Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose epirubicin neoadjuvant chemotherapy in Chinese breast cancer patients
ChiCTR-IIR-16007817Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Feb 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of epirubicin in breast cancer, Luminal B breast cancer and triple-negative breast cancer (TNBC) (3 arms), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: Pathologic complete response rate (pCR). Planned start Feb 2016; status: not yet recruiting.
02
Drugs
epirubicin
03
Conditions
breast cancerLuminal B breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR-IIR-16007817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16007817.